floxuridine has been researched along with Melena in 1 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Melena: The black, tarry, foul-smelling FECES that contain degraded blood.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| HARTMANN, JR | 1 |
| ORIGENES, ML | 1 |
| MURPHY, ML | 1 |
| SITARZ, A | 1 |
| ERLANDSON, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
1 other study available for floxuridine and Melena
| Article | Year |
|---|---|
EFFECTS OF 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) AND 5-FLUOROURACIL (NSC-19893) ON CHILDHOOD LEUKEMIA.
Topics: Bone Marrow Examination; Child; Floxuridine; Fluorouracil; Leukemia; Leukopenia; Melena; Nausea; Tox | 1964 |